CURRENT CASE STUDIES

FUCASO is a revolutionary BCMA-targeting CAR-T therapy by IASO BIO, offering unparalleled efficacy and safety for relapsed or refractory multiple myeloma. With high response rates, durable remission, and a robust safety profile, FUCASO provides new hope for patients and sets a new standard in CAR-T therapy.

CAR-T Therapy, short for Chimeric Antigen Receptor T-Cell Immunotherapy, is an advanced gene therapy method that involves genetically modifying a patient's own T cells to target and destroy cancer cells. Unlike traditional medications, CAR-T therapy is tailored to each patient and requires collecting T cells from the patient's blood before reinfusing them back into the body after genetic engineering.